S&P 500 Healthcare Sector SEC Filings — May 06, 2026

06-05-2026

Castle Biosciences reported Q1 2026 revenue of $83.7 million, a decline from $88.0 million in Q1 2025, primarily due to DecisionDx-SCC Medicare coverage changes effective April 2025, commercial refocus, and IDgenetix discontinuation in May 2025, though non-dermatologic revenues rose to $42.6 million from $25.0 million and core drivers (DecisionDx-Melanoma and TissueCypher) test volumes surged 36% YoY. DecisionDx-Melanoma volumes grew 16% to 10,021 reports while TissueCypher jumped 58% to 11,745, but DecisionDx-SCC volumes fell to 3,702 from 4,375. The company raised FY2026 revenue guidance to $345-355 million from $340-350 million, despite Adjusted EBITDA dropping to $(5.1) million from $13.0 million.

• ·Gross margin improved to 73% from 49% YoY, driven by absence of $20.1M one-time amortization acceleration in prior year; Adjusted Gross Margin was 76% vs 81%.
• ·Net loss narrowed to $14.5M ($0.49 per share) from $25.8M ($0.90 per share) YoY.
• ·Q1 2026 net cash used in operations $22.1M, including $28.8M in non-recurring bonuses and benefits.

06-05-2026

For the three months ended March 31, 2026, Atmos Energy Corp reported net income of $581,899 thousand, up 19.8% YoY from $485,576 thousand, with operating income rising 21.6% to $764,804 thousand due to lower purchased gas costs (-14.3%) and operation & maintenance expenses (-16.1%), though total operating revenues were nearly flat (+0.6%) at $1,962,402 thousand as Distribution segment revenues dipped slightly (-0.3%) while Pipeline & Storage grew 11.7%. Over six months, net income increased 17.6% to $984,863 thousand and revenues rose 5.7% to $3,304,987 thousand, but operating cash flow declined 14.3% to $1,031,547 thousand amid elevated capital expenditures of $2,036,935 thousand (up 17.7%). Cash dividends per share doubled to $2.00 from $1.74 YoY.

• ·Regulatory assets increased to $708,505 thousand at March 31, 2026 from $608,729 thousand at September 30, 2025.
• ·Regulatory liabilities slightly up to $1,277,855 thousand at March 31, 2026 from $1,269,648 thousand at September 30, 2025.
• ·Basic net income per share $3.49 for three months 2026 vs $3.05 in 2025; diluted $3.47 vs $3.03.
• ·Cash and cash equivalents at end of six months period: $127,108 thousand in 2026 vs $545,120 thousand in 2025 (net decrease).

06-05-2026

NewAmsterdam Pharma Company N.V. has issued a proxy statement for its Annual General Meeting on June 2, 2026, seeking shareholder approval for adoption of the Dutch statutory annual accounts for FY ended December 31, 2025, discharge of director liability, reappointment of Deloitte Accountants B.V. as auditor, reappointment of non-executive directors John W. Smither and Janneke van der Kamp, extensions of share issuance authorizations, approval of the 2026 Employee Stock Purchase Plan, and a non-binding advisory vote on 2025 named executive officer compensation. The record date is May 5, 2026, with attendance notices and proxies due by 11:59 p.m. ET on May 31, 2026. No specific financial performance metrics or period-over-period comparisons are disclosed in the provided filing content.

• ·Annual General Meeting location: offices of NautaDutilh N.V., Beethovenstraat 400, 1082 PR Amsterdam, Netherlands at 5:00 p.m. CEST on June 2, 2026.
• ·Dutch statutory board report and annual accounts for FY 2025 available no later than May 18, 2026 on company website.
• ·Proxy submission options: toll-free telephone (1-800-690-6903), www.proxyvote.com, or mail.

06-05-2026

Woori Financial Group Inc. (WFG) filed a Rule 425 communication on May 6, 2026, regarding its proposed small-scale share exchange with TONGYANG Life Insurance Co., Ltd., including a form for shareholders to submit written notices of dissent to the board's resolution replacing shareholder approval. Key prior documents include 'Decisions on Share Exchange' furnished on April 24, 2026, with a Form F-4 registration statement to be filed later. No financial metrics or performance data are disclosed in this procedural filing.

• ·Commission File No.: 001-31811
• ·Dissent form specifies common shares owned and dissenting shares

06-05-2026

BeOne Medicines reported first quarter 2026 total global revenues of $1.5 billion, up 35% YoY from $1.1 billion, driven by BRUKINSA global sales of $1.1 billion (+38% YoY) and net product revenues of $1.5 billion (+34% YoY). GAAP diluted EPS per ADS was $1.96, up from $0.01, with GAAP net income of $227 million and free cash flow of $161 million, while operating expenses rose 16% to $1.1 billion due to higher R&D (+12%) and SG&A (+21%) investments. The company raised full-year 2026 revenue guidance to $6.3-$6.5 billion from $6.2-$6.4 billion, with gross margins in the high-80% range.

• ·Gross margin improved to 89% from 85% YoY due to higher BRUKINSA sales mix and productivity gains.
• ·SG&A expenses as % of product sales declined to 37% from 41% YoY.
• ·Updated FY 2026 GAAP operating income guidance raised to $750-850 million from $700-800 million.
• ·Over 20 abstracts accepted for ASCO across hematology and solid tumor pipeline.
• ·Entered exclusive option with Huahui Health for worldwide rights to HH160 (BON-110).

06-05-2026

Louisiana-Pacific Corporation (LP) reported Q1 2026 consolidated net sales of $574 million, down $149 million or approximately 21% YoY from $723 million, with Siding sales decreasing 10% to $360 million due to lower volumes despite higher prices, and OSB sales plunging 37% to $168 million on lower prices and volumes. Adjusted EBITDA fell $80 million to $82 million, and net income dropped $64 million to $27 million ($0.39 per diluted share). Guidance indicates continued challenges with Siding net sales ~4% down in Q2 and ~2% for FY2026, alongside negative OSB Adjusted EBITDA of -$10 million in Q2 and -$40 million for the year.

• ·Siding Q1 price increase of 9% offset by 18% volume decline
• ·OSB Structural Solutions Q1 price down 21%, volume down 18%; Commodity OSB price down 31%, volume down 12%
• ·Other operations net sales down $8 million, Adjusted EBITDA down $9 million in Q1
• ·FY2026 capex guidance ~$390 million ($200 million strategic growth, $190 million sustaining maintenance)
• ·Conference call held May 6, 2026 at 11 a.m. ET

06-05-2026

American Financial & Tax Strategies Inc filed its 13F-HR report on May 6, 2026, disclosing total holdings of $205760881 across 97 positions as of March 31, 2026. The portfolio consists entirely of sole discretionary shares in a diversified mix of ETFs and individual stocks, with no other voting authority or options reported. Largest positions include Vanguard Total International Bond ETF (233767 shares, $11232481), Vanguard Russell 1000 Growth ETF (80362 shares, $8814950), and Schwab U.S. Large-Cap Value ETF (109752 shares, $3347436).

• ·All 97 positions held with sole voting power (SH SOLE).
• ·No put/call options or other manager authority reported.
• ·Notable stock holdings: Apple Inc (4150 shares, $1053258), Amazon.com Inc (4517 shares, $940756), Cisco Sys Inc (19140 shares, $1485073).

06-05-2026

Wall Street Financial Group, Inc. filed its 13F-HR on May 6, 2026, disclosing 667 equity holdings as of March 31, 2026, with a total market value of $168.87 billion, all managed with sole investment and voting discretion. Largest positions include NVIDIA Corporation at $7.38 billion (42,334 shares), Apple Inc. at $5.22 billion (20,567 shares), Palantir Technologies Inc. at $1.90 billion (13,022 shares), Eli Lilly & Co. at $2.00 billion (2,176 shares), and Tesla Inc. at $1.68 billion (4,532 shares). No shared discretion, performance changes, or other voting powers were reported.

• ·All 667 positions held with sole investment discretion and sole voting power (no shared power reported)
• ·Filing covers period ending 03/31/2026

06-05-2026

Bread Financial Holdings, Inc. announced the pricing of an underwritten public offering of 4,800,000 depositary shares, each representing a 1/40th interest in a share of its 8.875% Fixed Rate Reset Non-Cumulative Perpetual Preferred Stock, Series B, with a liquidation preference of $25 per depositary share. The underwriters, led by Morgan Stanley & Co., LLC and others, were granted an option to purchase up to an additional 720,000 depositary shares within 30 days. Net proceeds will be used for general corporate purposes, potentially including contributions to subsidiary Comenity Capital Bank and share repurchases.

• ·Offering registered under Securities Act on Form S-3 (Registration No. 333-291573).
• ·Prospectus supplement dated May 5, 2026, to be filed pursuant to Rule 424(b).
• ·Underwriting agreement dated May 5, 2026.

06-05-2026

Corebridge Financial discussed its proposed merger with Equitable Holdings, Inc., highlighting complementary product suites, no apprehension from distribution partners, and expected expense synergies alongside revenue opportunities like $100B in assets to AllianceBernstein and $30B upside in wealth management cross-sell/upsell. Management plans share repurchases post-shareholder vote in December and deployment of remaining capital via accelerated share repurchase post-close, with pro forma guidance of $4B cash and $5B earnings implying ~80% free cash flow conversion. However, Individual Retirement sales were roughly flat YoY, suggesting tempered industry flows.

• ·No dis-synergies identified from merger; distribution partner overlap de minimis.
• ·Shareholder vote expected December 2026; Investor Day planned first half 2027 for detailed synergy guidance.
• ·BDC debt exposure features conservative leverage, low LTVs, high diversification, and solid investment grade ratings with no equity exposure.
• ·AI focus on front-end distribution enablement and back-end servicing (e.g., digital agents for group retirement plans).

06-05-2026

Futurewave Acquisition Corp, a Cayman Islands blank check company formed on February 16, 2026, has filed an S-1 registration statement for an IPO of 5,000,000 units (or 5,750,000 if over-allotment exercised) at $10.00 per unit, targeting gross proceeds of $50,000,000, with $10.00 per unit deposited into a U.S. trust account for an initial business combination. Net proceeds before expenses are $49,625,000 after $375,000 in underwriting discounts. However, public shareholders face substantial dilution, with pro forma net tangible book value per share dropping to as low as $0.29 (maximum redemptions) from an adjusted offering price of $8.00, resulting in dilution up to $7.73 per share.

• ·Company qualifies as emerging growth company with reduced reporting requirements.
• ·Units expected to list on Nasdaq as FWAC, FWACW, FWACR.
• ·Founder shares subject to up to 321,750 forfeiture if over-allotment not exercised.
• ·Pro forma net tangible book value per share without over-allotment: $5.09 (25% redemptions), $4.12 (50%), $2.68 (75%), $0.29 (100%).
• ·Dilution to public shareholders without over-allotment: $2.91 (25% redemptions), $3.88 (50%), $5.32 (75%), $7.71 (100%).
• ·Financial data as of March 31, 2026.

06-05-2026

Prospect Financial Group LLC filed its Form 13F-HR on May 6, 2026, reporting holdings as of March 31, 2026, in approximately 63 securities consisting primarily of Dimensional and Vanguard ETFs along with individual stocks such as Abbvie, Alphabet, Amazon, Apple, and Nvidia. Largest positions include Dimensional ETF Trust Emerging Mkts Core Equity at 10913096 (thousands USD), Dimensional ETF Trust US Core Equity 1 at 8177095 (thousands USD), and Vanguard Bd Index Fds Total Bnd Mrkt at 8040826 (thousands USD). All positions are held with sole voting power and zero shared power.

• ·Filing effective date: May 6, 2026
• ·Period end date: March 31, 2026
• ·All holdings reported as SH SOLE with 0 shared power
• ·Business address: 3617 N. Albemarle St., Arlington, VA 22207
• ·SEC file number: 028-24920

06-05-2026

Anthracite Investment Company, Inc. filed a 13F-HR institutional holdings report for the period ending March 31, 2026, on May 6, 2026. The filing reports no holdings, with all values indicated as 0 (e.g., 000000000 shares sole). It was signed by William B. Holloway, Jr., Chief Operating Officer.

• ·CIK: 0001809930
• ·SEC File Number: 028-23657
• ·State of Incorporation: TX
• ·Fiscal Year End: 12/31
• ·Business Address: 640 Taylor Street, Suite 2400, Fort Worth, TX 76102

06-05-2026

Pinnacle Financial Partners reported Q1 2026 net income of $150M, up 7% YoY from $140M, driven by net interest income growth of 156% to $933M and non-interest revenue up 193% to $284M, largely from the Synovus acquisition which doubled total assets to $122,766M and loans to $84,255M net. However, non-interest expenses surged 246% to $952M due to $275M merger costs and higher salaries, provision for credit losses rose 347% to $76M, EPS diluted to $0.89 from $1.78, and comprehensive income fell to $48M from $142M amid OCI losses.

• ·Merger-related expense of $275M in Q1 2026.
• ·Allowance for loan losses increased to $942M from $442M QoQ.
• ·Acquisition net cash impact: $2,537M.
• ·Cash dividends on common stock: $0.50 per share ($75M total) in Q1 2026 vs $0.24 ($19M) in Q1 2025.

06-05-2026

Premier Financial Group filed its 13F-HR on May 6, 2026, disclosing $587,261,201 in holdings across 46 ETFs as of March 31, 2026. The portfolio is dominated by Dimensional ETFs, including the largest position in Dimensional International High Profitability ETF valued at $211,076,409 (641,693 shares), followed by Dimensional U.S. Small Cap ETF at $85,263,650 and Dimensional U.S. Targeted Value ETF at $74,805,720. All positions are held with sole voting power.

• ·All holdings reported with sole voting authority and no other managers
• ·Filer CIK: 0001989061, SEC File Number: 028-25731
• ·Business address: 725 6th Street, Eureka, CA 95501

06-05-2026

Edgewell Personal Care reported Q2 FY26 net sales of $519.5 million from continuing operations, up 0.6% YoY due to currency but organic sales down 2.4%, with Wet Shave up 3.0% reported (organic -0.7%) while Sun and Skin Care declined 2.5% (organic -4.5%). Adjusted EPS fell to $0.60 from $0.69 and adjusted EBITDA to $73.8 million from $84.7 million, though results exceeded expectations; gross margin dropped 410 basis points to 41.8%. The company reaffirmed most FY26 outlook but lowered GAAP EPS guidance to flat to $0.40 and raised expected restructuring charges to $90 million, while returning $22.9 million to shareholders via dividends and repurchases.

• ·Adjusted net debt leverage ratio of 4.0x as of Q2 FY26 end.
• ·FY26 outlook: Organic net sales -1.0% to +2.0%; Adjusted EPS $1.70-$2.10; Adjusted EBITDA $245-$265M; Adjusted free cash flow $80-$110M; Adjusted net debt leverage 3.3x-3.5x at FY end.
• ·Q2 dividend declared $0.15 per share, payable July 9, 2026.
• ·Productivity savings of 220 basis points offset by 420 bps inflation/tariffs, 70 bps unfavorable mix/promos, 40 bps currency.

06-05-2026

News Corporation filed an 8-K disclosing information provided to the Australian Securities Exchange (ASX) regarding its ongoing $1 billion stock repurchase program authorizing the acquisition of Class A and Class B common stock. The disclosures, attached as Exhibits 99.1 and 99.2, fulfill daily ASX reporting requirements and include forward-looking statements about potential repurchases subject to market conditions and other factors. No specific repurchase transactions are detailed in the filing.

• ·Filing date: May 6, 2026; Date of earliest event reported: May 5, 2026
• ·Securities registered: Class A Common Stock (NWSA, par value $0.01), Class B Common Stock (NWS, par value $0.01) on Nasdaq Global Select Market
• ·Principal executive offices: 1211 Avenue of the Americas, New York, New York 10036

06-05-2026

For the three months ended March 31, 2026, CVS Health reported total revenues of $100,426 million, up 6.2% YoY from $94,588 million, with strong growth in products (+7.8% to $62,226 million) and services (+7.1% to $3,835 million), while premiums grew modestly +3.0% to $33,791 million. Net income attributable to CVS Health surged 65.4% YoY to $2,943 million, with diluted EPS rising to $2.30 from $1.41. However, net cash provided by operating activities declined 6.7% to $4,249 million from $4,556 million, operating expenses dipped slightly -0.7% but total operating costs rose 5.0%, and total assets decreased marginally to $252,974 million from $253,538 million at December 31, 2025.

• ·Cash and cash equivalents increased QoQ to $9,542 million from $8,453 million.
• ·Inventories decreased QoQ to $17,770 million from $19,246 million.
• ·Current liabilities declined QoQ to $86,406 million from $88,692 million.
• ·Shareholders' equity attributable to CVS Health rose to $77,456 million from $75,214 million at year-end.

06-05-2026

Anavex Life Sciences Corp. appointed Terrie Kellmeyer, PhD, former Senior Vice President of Clinical Development, as Interim Chief Executive Officer following the departure of President and CEO Christopher Missling, PhD, on April 30, 2026. Dr. Kellmeyer will advance the company's pipeline, including lead candidate oral blarcamesine for early Alzheimer’s disease, leveraging her extensive experience in regulatory submissions and clinical development. The company highlighted a strong cash balance with no long-term debt but disclosed a delay in filing its Form 10-Q for the quarter ended March 31, 2026, via a Form 12b-25 extension.

• ·CEO departure and board resignation requested on April 30, 2026
• ·Form 10-Q extension via Form 12b-25 for quarter ended March 31, 2026
• ·Planned conference call and webcast for second quarter 2026 financial results

06-05-2026

New York Times Co filed an 8-K on May 6, 2026, under Item 2.02 disclosing results of operations and financial condition, accompanied by Item 9.01 for financial statements and exhibits. No specific revenue, earnings, margins, period-over-period changes, guidance, or other quantitative metrics were detailed in the provided filing information. This is a standard earnings-related multi-item disclosure without disclosed financial impacts.

06-05-2026

06-05-2026

Cincinnati Financial Corporation held its annual shareholder meeting on May 2, 2026, where all 13 director nominees were elected with majority support, though Gretchen W. Schar and Dirk J. Debbink faced notable opposition (12.8 million and 11.4 million against votes, respectively). Management-sponsored proposals to amend the articles of incorporation, approve executive compensation on an advisory basis, and ratify Deloitte & Touche LLP as auditors passed overwhelmingly, while a shareholder proposal for special meeting rights failed decisively (33.3 million for vs. 89.2 million against). The company issued news releases confirming the meetings and declaring a regular quarterly cash dividend.

• ·Proposal 2 (Amend Articles): 116,689,476 For, 6,061,037 Against
• ·Proposal 3 (Shareholder Special Meeting Rights): 33,295,658 For, 89,213,135 Against
• ·Proposal 4 (Say-on-Pay): 118,190,863 For, 4,425,146 Against
• ·Proposal 5 (Auditor Ratification): 130,166,995 For, 6,131,653 Against

06-05-2026

06-05-2026

Dunhill Financial, LLC filed its Form 13F-HR on May 6, 2026, disclosing 1,857 equity positions totaling $424,397,963 as of March 31, 2026, all held with sole voting power. Notable holdings include 5,816 shares of AutoZone Inc., 1,566 shares of TransDigm Group Inc., 860 shares of RBC Bearings Inc., and 691 shares of Medpace Hldgs Inc., spanning diverse sectors with no reported changes from prior periods in this snapshot filing. The disclosure reflects a broad, diversified portfolio without highlighted gains or losses.

• ·Filing period end date: March 31, 2026
• ·All reported positions held with sole voting power and sole discretionary power
• ·Firm CIK: 0001948904; SEC file number: 028-23375
• ·Business address: Swan Court Unit 109, 11 Worple Road, London X0 SW19 4JS

06-05-2026

BOK Financial reported net interest income down $2.7 million QoQ for Q1 2026, driven by higher interest expense and lower interest revenue, while tax-equivalent net interest income increased $26.4 million YoY. Total fees and commissions declined 2% QoQ to $209.8M but rose 14% YoY, with mortgage banking revenue up 10% QoQ and brokerage revenue down 8% QoQ. Total other operating revenue fell 14% QoQ to $211.3M amid losses on derivatives and fair value securities, though up 14% YoY; assets under management or administration were $123.6B, slightly down QoQ.

• ·Mortgage loan refinances to mortgage loans funded for sale increased to 30% in Q1 2026 from 27% in Q4 2025.
• ·Realized margin on funded mortgage loans improved to 1.22% in Q1 2026 from 1.10% in Q4 2025.
• ·Average primary mortgage interest rates declined to 6.11% in Q1 2026 from 6.23% in Q4 2025.

06-05-2026

The New York State Common Retirement Fund filed its quarterly 13F-HR on May 6, 2026, reporting equity holdings as of March 31, 2026, totaling exactly 71577517831 USD across 3132 positions. Notable top holdings include Amazon.com Inc. (2415839320 USD, 11599555 shares), Alphabet Inc. Class A (2042485194 USD, 7102814 shares), and Alphabet Inc. Class C (1634267524 USD, 5697091 shares). No period-over-period comparisons or changes are disclosed in this filing.

• ·Filing covers period ending 2026-03-31
• ·All holdings reported as sole discretionary with 0 shared or other manager voting/disposition authority
• ·Fund address: Office of the State Comptroller, 14th Floor, 110 State Street, Albany, NY 12236

06-05-2026

LPL Financial LLC filed its 13F-HR on May 6, 2026, reporting discretionary equity holdings as of March 31, 2026, across hundreds of stocks and ETFs. Top positions include AbbVie Inc. at $858055825, Advanced Micro Devices Inc. at $493385729, and Abbott Laboratories at $222006559, with no prior period comparisons provided in the filing. The portfolio features significant allocations to AB Active ETFs and other diversified securities.

• ·Filing period end date: 2026-03-31
• ·Filed as of date: 2026-05-06
• ·SEC file number: 028-12526
• ·Numerous positions held as SOLE discretion

06-05-2026

WoodTrust Financial Corp filed its 13F-HR report on May 06, 2026, disclosing $774,796,000 in equity holdings across 238 positions as of March 31, 2026. The portfolio is diversified with significant exposure to international ETFs, including iShares TR MSCI EAFE ETF at $96,381,000 and Vanguard Intl Equity Index F FTSE EMR Mkt ETF at $30,974,000, alongside large-cap stocks such as Johnson & Johnson ($25,226,000), Microsoft Corp ($22,781,000), Amazon.com Inc ($21,375,000), and Apple Inc ($19,835,000). No period-over-period changes or performance metrics are provided in the filing.

• ·EIN: 391082300
• ·State of Incorporation: WI
• ·Business Phone: 715-423-6800

06-05-2026

Bankwell Financial Group, Inc. reported Q1 2026 net income of $11,275 thousand, up 64% YoY from $6,888 thousand, with net interest income rising 22% to $26,886 thousand and gains from loan sales surging to $2,425 thousand. However, noninterest expenses increased 19% YoY to $16,889 thousand, driven by higher salaries and employee benefits, while total investment securities declined 2% QoQ to $187,574 thousand and cash equivalents fell 3% QoQ. Total assets edged up 0.4% QoQ to $3,373,859 thousand, supported by 1% growth in net loans to $2,832,678 thousand and 2% rise in deposits.

• ·Credit provision was a $(1,029) thousand credit in Q1 2026 vs $463 thousand provision in Q1 2025.
• ·Dividends per common share remained flat at $0.20.
• ·Basic EPS increased to $1.42 from $0.88 YoY.
• ·FHLB advances reduced to $60,000 thousand from $110,000 thousand QoQ.

06-05-2026

Cornerstone Financial Group, LLC /NE/ filed a 13F-HR report disclosing $155805232 in equity holdings as of March 31, 2026, across 73 positions primarily consisting of ETFs and select individual stocks. Largest holdings include SPDR Series Trust (78464A805) at $13615461, Dimensional ETF Trust US Equity Market (25434V401) at $11695262, and SPDR S&P 500 ETF (78463X889) at $9304482. All positions are held with sole voting authority and no reported changes in shared discretion or other managers.

• ·All holdings reported as sole discretionary with no put/call positions or other manager discretion.
• ·Firm address: 11225 Davenport St, Ste 102, Omaha, NE 68154.
• ·Report filed May 6, 2026 for quarter ended March 31, 2026.

06-05-2026

Oxford Financial Group, Ltd. LLC filed its Form 13F-HR on May 6, 2026, disclosing discretionary equity holdings as of March 31, 2026, with a total portfolio market value of $1,857,042,749 across 302 positions held solely. Top holdings by value include Listed FDS TR Horizon Kinetics ETF ($205,504,360), Intuitive Surgical Inc. ($167,694,793), and Eli Lilly & Co. ($119,219,804). The portfolio is diversified across individual stocks like Apple Inc. ($42,021,286) and numerous iShares and other ETFs, with no prior period data provided for comparison.

• ·Filing covers sole discretionary holdings only (no shared or other manager discretion indicated)
• ·Portfolio includes significant ETF exposure, such as iShares Core S&P 500 ETF (89,481 shares, $58,449,770)

06-05-2026

Zhang Financial LLC filed its 13F-HR on May 6, 2026, reporting holdings as of March 31, 2026, with a total portfolio value of $2892186546 across 367 positions, all held with sole voting authority. Top holdings include Vanguard S&P 500 ETF ($195046744), Vanguard Total Stock Market ETF ($180750841), Dimensional US Equity ETF ($179654455), iShares Core S&P Total Stock ETF ($168345379), and Vanguard Intermediate-Term Treasury ETF ($145881467). The portfolio emphasizes diversified index ETFs and broad market exposure with no reported changes or performance metrics.

• ·All 367 positions held with sole voting authority (SH SOLE)
• ·Business address: 5931 Oakland Dr., Portage, MI 49024
• ·Phone: 269-385-5705
• ·SEC file number: 028-19517
• ·Not an amendment (false)

06-05-2026

Gryphon Financial Partners LLC filed its 13F-HR on May 6, 2026, disclosing total holdings of $975768834 as of March 31, 2026, across 371 positions. Top holdings include iShares Core S&P 500 ETF at $191491934, Apple Inc. at $44878251, Vanguard Total Stock Market ETF at $35050842, Warner Bros. Discovery Inc. at $29587876, and NVIDIA Corporation at $28695349. The portfolio is heavily weighted toward ETFs and large-cap U.S. equities with no disclosed period-over-period changes in this filing.

• ·Filed under SEC file number 028-18308
• ·CIK: 0001729094
• ·Business address: 325 John H. McConnell Blvd. Suite 425, Columbus, OH 43215
• ·Adviser ID: 801-110583

06-05-2026

LCI Industries filed an 8-K on May 6, 2026, furnishing the transcript of its earnings conference call dated May 5, 2026, pursuant to Regulation FD Disclosure (Item 7.01). The transcript is provided as Exhibit 99.1 and is not deemed 'filed' for purposes of Section 18 of the Securities Act. No specific financial metrics or performance details are included in the filing body.

• ·Filing Date: May 6, 2026
• ·Date of Earliest Event Reported: May 5, 2026
• ·Items Reported: 7.01 (Regulation FD Disclosure), 9.01 (Financial Statements and Exhibits)
• ·Securities: Common Stock, $.01 par value (LCII, New York Stock Exchange)

06-05-2026

Patriot Financial Partners GP II, L.P. filed its 13F-HR report as of March 31, 2026, disclosing a total portfolio value of $388,326,607 across 12 sole discretionary equity positions in financial institutions. The largest holding is Metropolitan Bank Holding Corp. Common Stock valued at $63,707,188 (764,884 shares), followed by Equity Bancshares, Inc. ($53,041,661, 1,194,363 shares) and TowneBank ($51,115,875, 1,518,143 shares). No prior period comparisons are provided in the filing.

• ·Filing submitted on May 06, 2026 for period ending March 31, 2026
• ·All positions reported as sole discretionary (SH SOLE) with zero shared or other authority
• ·Business address: Four Radnor Corporate Center, 100 Matsonford Road, Suite 210, Radnor, PA 19087

06-05-2026

Sight Sciences reported first quarter 2026 revenue of $19.7 million, up 13% YoY, with Interventional Dry Eye surging 244% to $1.4 million while Interventional Glaucoma grew modestly 7% to $18.3 million; gross margin held flat at 86%. Operating expenses rose 2% to $29.4 million due to a $5.4 million one-time litigation success fee, though adjusted operating expenses fell 14% to $21.2 million and cash usage improved 40% to $7.0 million, leaving cash at $85.0 million. The company raised full-year 2026 revenue guidance to $83.0-89.0 million (7-15% growth vs. 2025) and secured a patent infringement judgment against Alcon for $55.4 million in damages plus a 10% ongoing royalty on Hydrus Microstent revenue, subject to appeal.

• ·R&D expenses decreased 43% YoY to $2.5 million in Q1 2026.
• ·SG&A expenses increased 9% YoY to $26.8 million in Q1 2026.
• ·Net loss per share improved to -$0.24 from -$0.28 YoY.
• ·FY2026 Interventional Glaucoma guidance: $77.0-81.0 million (2-7% growth vs. 2025).
• ·FY2026 Interventional Dry Eye guidance: $6.0-8.0 million (vs. $1.6 million in 2025).
• ·FY2026 adjusted operating expenses guidance: $93.0-96.0 million (+6-9% vs. 2025).
• ·U.S. District Court for the District of Delaware judgment subject to appeal.
• ·Conference call held May 6, 2026, at 1:30 p.m. PT.

06-05-2026

CoreCivic reported strong Q1 2026 results with total revenue of $614.7 million, up 25.8% YoY, net income of $37.9 million, up 51.0% YoY, and Adjusted EBITDA of $110.1 million, up 36.0% YoY, driven by activations of previously idled facilities including Dilley, West Tennessee, California City, and Diamondback. However, results were partially offset by a mission change at Trousdale Turner Correctional Center causing temporarily lower populations and higher expenses, higher G&A and interest costs, and a recent temporary downturn in ICE populations due to DHS adjustments; state revenue grew modestly by only 3.6% YoY. The company announced the acquisition of Clinical Solutions Pharmacy for ~$148 million, repurchased 2.3 million shares for $44.7 million, added a $100 million incremental term loan, and raised full-year 2026 guidance including Adjusted Diluted EPS to $1.53-$1.63.

• ·Occupancy in Safety and Community segments reached 79.6% in Q1 2026 vs 77.0% in Q1 2025.
• ·Leverage (net debt to Adjusted EBITDA TTM) at 2.8x as of Q1 2026 end.
• ·Updated 2026 guidance: Adjusted EBITDA $453.8M to $461.8M; expects CSP to add $0.03-$0.05 EPS and Midwest facility $0.05-$0.06 EPS remainder of 2026.
• ·CSP serves over 600 correctional facilities across 28 states.
• ·$255.8M remaining under share repurchase program as of March 31, 2026.

06-05-2026

Revolution Medicines announced positive topline Phase 3 RASolute 302 results for daraxonrasib in second-line PDAC, demonstrating median OS of 13.2 months vs. 6.7 months for chemotherapy (HR 0.40; p<0.0001), with plans for regulatory submissions including FDA under National Priority Voucher and ASCO plenary presentation. The company raised $2,225.0 million in gross proceeds from concurrent financings, with net proceeds of $2.1 billion added to a $1.9 billion Q1 cash position. However, Q1 net loss widened to $453.8 million from $213.4 million YoY, driven by R&D expenses of $344.0 million (up from $205.7 million) and G&A of $101.3 million (up from $35.0 million), primarily due to higher stock-based compensation from equity program changes.

• ·Updated full-year 2026 GAAP operating expenses guidance to $1.7-1.8 billion, with stock-based compensation now estimated at $260-280 million (increased by ~$80 million).
• ·Daraxonrasib received FDA Breakthrough Therapy Designation, Commissioner's National Priority Voucher, and EMA Orphan Drug Designation for pancreatic cancer.
• ·Ongoing Phase 3 trials include RASolute 303 (1L metastatic PDAC), RASolute 304 (adjuvant PDAC), RASolve 301 (NSCLC), and planned RASolute 309 (H2 2026) and RASolve 308 (H1 2026).

06-05-2026

Chime reported Q1 2026 revenue of $647 million, up 25% YoY, with platform-related revenue surging 50% to $215 million but payments revenue growing more modestly at 15% to $433 million (19% including OIT); the company achieved its first GAAP profitable quarter as a public company with $53 million net income and raised FY2026 revenue guidance to $2.66-2.69 billion (+22-23% YoY). Active Members reached 10.2 million (+19% YoY), ARPAM increased 5% to $263, and Purchase Volume rose 12% to $39 billion (15% including OIT). Chime also announced a $200 million share repurchase authorization.

• ·Gross margin of 90% in Q1 2026.
• ·Transaction profit margin of 76% (non-GAAP) in Q1 2026.
• ·Adjusted EBITDA incremental margin of 73% in Q1 2026.
• ·Signed four new employer partners for Chime Enterprise, including First Student (65,000+ employees).
• ·AI-assisted code development scaled from 29% to 84% of code shipped in four months.

06-05-2026

Core Scientific reported first quarter 2026 total revenue of $115.2 million, up 45% YoY from $79.5 million, primarily driven by colocation revenue surging to $77.5 million from $8.6 million amid a strategic shift to high-density colocation services. However, digital asset self-mining revenue declined 55% YoY to $30.1 million from $67.2 million due to lower bitcoin mined and prices, contributing to a net loss of $347.2 million versus net income of $576.3 million in Q1 2025, largely from $266.5 million in non-cash impairment charges. Adjusted EBITDA improved to $4.4 million from $(6.1) million, while capital expenditures rose sharply to $389.2 million.

• ·Gross power capacity pipeline expanded to 4.5 GW.
• ·Closed $3.3 billion 7.75% senior secured notes due 2031.
• ·Of Q1 capex $389.2M, $129.9M funded by CoreWeave.
• ·Colocation gross margin improved to 57% from 5% YoY.
• ·Bitcoin holdings: $37.3 million as of March 31, 2026.

06-05-2026

Hershey Financial Advisers, LLC filed a 13F-HR report disclosing 124 equity positions with a total market value of $115799771 as of March 31, 2026. The portfolio is diversified across ETFs (e.g., iShares Convertible Bond ETF valued at $6404729, SPDR Series Trust at $4656913) and individual stocks (e.g., FedEx Corp at $1192491, Corning Inc at $1505052). No prior period comparisons or performance changes are provided in the filing.

• ·Filing date: May 06, 2026
• ·Period end date: March 31, 2026
• ·Business address: 120 North Pointe Blvd Suite 302, Lancaster, PA 17601

06-05-2026

FrontView REIT reported Q1 2026 revenues of $18,185 thousand, up 12% YoY from $16,243 thousand, with AFFO of $9,490 thousand ($0.34 per share), up 15% from $8,238 thousand ($0.30 per share), and net income of $400 thousand versus a $1,337 thousand loss in Q1 2025. The company acquired 10 properties for $33,857 thousand and sold 5 for $9,660 thousand, resulting in net investment activity of $24,197 thousand, while lowering leverage to 5.3x Net Debt to Annualized Adjusted EBITDAre; however, the quarterly dividend remained flat at $0.215 per share. Full-year 2026 AFFO per share guidance was raised to $1.29-$1.33 from $1.27-$1.32.

• ·Portfolio occupancy at 98.7% with weighted average lease term of 7.3 years.
• ·Total liquidity of $195,294 thousand including $136,000 thousand undrawn revolver.
• ·Fixed Charge Coverage Ratio of 3.5x.
• ·Conference call scheduled for May 7, 2026, at 10:00 a.m. Central Time.
• ·Quarterly dividend of $0.215 per common share payable July 15, 2026, to record date June 30, 2026.

06-05-2026

Orrstown Financial Services, Inc. elected Adam L. Metz, currently Senior Executive Vice President and Chief Operating Officer, as President, Chief Executive Officer, and Director of the Company and Orrstown Bank, effective June 1, 2026, upon the retirement of Thomas R. Quinn, Jr. from those positions. At the annual shareholder meeting on May 5, 2026, four Class A directors received an average of 95.81% support, the advisory Say-on-Pay vote for Named Executive Officers was approved by 94.91% of votes cast, and Crowe LLP's appointment as independent auditor for the fiscal year ending December 31, 2026, was ratified by 99.50% of votes cast.

• ·Adam L. Metz, age 54, joined in 2016; previously Senior Executive Vice President and Chief Operating Officer (since Feb 2025), Executive Vice President and Chief Revenue Officer (Feb 2019-Feb 2025), Executive Vice President and Chief Lending Officer (2016-Feb 2019), and Senior Vice President and Chief Lending Officer at Metro Bank (2011-2016).
• ·Mr. Metz to serve as Class B Director with term expiring at 2028 Annual Meeting of Shareholders.
• ·No family relationships or Item 404(a) disclosures for Mr. Metz.

06-05-2026

Green Thumb Industries reported first quarter 2026 revenue of $300.2 million, up 7.4% YoY from $279.5 million, driven by retail growth in new markets like Minnesota, with Normalized EBITDA rising to $93.5 million or 31.2% of revenue from $85.2 million. However, same-store sales declined 0.5%, Consumer Packaged Goods gross revenue fell 1.6%, gross margins compressed to 47.9% from 51.3%, and retail revenue growth slowed to 4.7%. The company generated $76.0 million in operating cash flow, held $344.5 million in cash, and repurchased 6.0 million shares for $33.3 million.

• ·Cash flow from operations: $76.0 million in Q1 2026.
• ·GAAP net income: $15.4 million or $0.07 per share (up from $8.3 million or $0.04 per share YoY).
• ·Year-to-date 2026 share repurchases: 13.4 million shares for $77.7 million; cumulative since Sep 2023: 29.0 million shares for $200.0 million.
• ·Operations in 14 U.S. markets.

06-05-2026

NVE Corporation reported Q4 FY2026 total revenue of $7.65 million, up 5% YoY from $7.27 million, driven by 6% growth in product sales but partially offset by a 19% decline in contract research and development revenue; net income increased 27% to $4.93 million or $1.02 per diluted share. For full FY2026, total revenue rose 1.8% to $26.3 million from $25.9 million, with 2.4% product sales growth offset by an 11% drop in contract R&D, while net income grew modestly 1% to $15.2 million or $3.14 per diluted share. The company announced a quarterly cash dividend of $1.00 per share, payable May 29, 2026 to shareholders of record May 18, 2026.

• ·Cash and cash equivalents decreased to $1.71 million as of March 31, 2026 from $8.04 million as of March 31, 2025.
• ·Total assets decreased to $60.38 million as of March 31, 2026 from $64.28 million as of March 31, 2025.
• ·Gross profit for FY2026 declined to $20.73 million from $21.64 million in FY2025.
• ·Research and development expenses decreased 13% YoY to $3.16 million for FY2026.
• ·Interest income slightly declined to $1.89 million for FY2026 from $1.91 million in FY2025.

06-05-2026

MVB Financial Corp reported net income attributable to parent of $5.2M for Q1 2026, up 45% YoY from $3.6M, supported by net interest income growth of 7% to $28.5M and noninterest income increase of 17% to $8.2M. However, provision for credit losses rose sharply 949% YoY to $1.9M from $0.2M, noninterest-bearing deposits declined 12% QoQ to $1.0B from $1.1B, and total other comprehensive loss net of tax was $4.2M. Total assets edged up 0.4% QoQ to $3.3B, with loans net up 2.6% to $2.4B.

• ·Earnings per common share - basic: $0.41 (Q1 2026) vs $0.28 (Q1 2025)
• ·Dividends on common stock: $0.17 per share ($2.2M total) in Q1 2026
• ·Subordinated debt decreased 54% QoQ to $34.0M from $74.0M
• ·Weighted-average shares outstanding - basic: 12,795,271 (Q1 2026) vs 12,948,178 (Q1 2025)

06-05-2026

Citizens Community Bancorp Inc. reported net income of $3,755 for Q1 2026, up 17.5% YoY from $3,197, supported by net interest income growth of 12.2% to $13,010 and non-interest income increase of 19.5% to $3,099. However, provision for credit losses shifted to an expense of $750 from a $250 reversal YoY, non-interest expenses rose 2.5% to $10,727, and cash dividends per share dropped sharply to $0.105 from $0.36. Total assets expanded 2.3% QoQ to $1,822,974, with deposits up 2.7% to $1,565,622, while loans receivable net grew 1.3% to $1,335,286.

• ·Cash and cash equivalents increased 28.2% QoQ to $149,202 from $118,853.
• ·Basic and diluted EPS both $0.39 in Q1 2026 vs $0.32 in Q1 2025.
• ·Net cash from operating activities $3,976 in Q1 2026 vs $1,613 in Q1 2025.
• ·Common stock repurchases occurred in 2025 totaling impact of $6,055 across quarters.